ArticleMolecules (Basel, Switzerland)2019
Thiostrepton: A Novel Therapeutic Drug Candidate for
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Identification of a Drug Candidate againstJournal of microbiology and biotechnology · 2025Article
- Deep learning-based prediction of chemical accumulation in a pathogenic mycobacterium.bioRxiv : the preprint server for biology · 2024Article
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Therapy ofMicroorganisms · 2024Review
- Thiostrepton induces cell death of acute myeloid leukemia blasts and the associated macrophage population.Haematologica · 2024Article
- Exploring antibiotic resistance mechanisms inFrontiers in microbiology · 2024Review
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- Treatment of non-tuberculosis mycobacteria skin infections.Frontiers in pharmacology · 2023Review
- Thiostrepton-Nanomedicine, a TLR9 Inhibitor, Attenuates Sepsis-Induced Inflammation in Mice.Mediators of inflammation · 2023Article
- Photocatalytic Reductive Olefin Hydrodifluoroalkylation Enabled by Tertiary Amine Reductants Compatible with Complex Systems.The Journal of organic chemistry · 2022Article
- Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.Medicinal research reviews · 2021Review
- A Screening of the MMV Pandemic Response Box Reveals Epetraborole as a New Potent Inhibitor againstInternational journal of molecular sciences · 2021Article
- Current Molecular Therapeutic Agents and Drug Candidates forFrontiers in pharmacology · 2021Review
- Bacteriocins: Potential for Human Health.Oxidative medicine and cellular longevity · 2021Review
- Omadacycline Potentiates Clarithromycin Activity AgainstFrontiers in pharmacology · 2021Article
- Sirtuin 3 is essential for host defense againstVirulence · 2020Article
- Etamycin as a NovelInternational journal of molecular sciences · 2020Article
- Thiopeptides Induce Proteasome-Independent Activation of Cellular Mitophagy.ACS chemical biology · 2020Article
- Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research.Pathogens (Basel, Switzerland) · 2020Review
- Rifamycin O, An Alternative Anti-Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.